Skip to main content

Table 2 BKV VP1 subtypes in renal patients detected by MS

From: Detection of BK virus in urine from renal transplant subjects by mass spectrometry

Patient

decoy cells

qPCR titer

dominant subtype

Sequence coverage VP1

aa

unique Peptides detected from dominant infection

co-infection subtype

Sequence coverage VP1

aa

unique Peptides detected from co-infection

3

> 10

negative

Ic

21%

40–64

K.TGVDAITEVECFLNPEMGDPDENLR.G

    
     

173–195

K.YPEGTITPKNPTAQSQVMNTDHK.A

    

5

>10

3.1×105

Ib-1

74%

171–181

R.TKYPDGTITPK.N

IV

40%

94–135

R.IPLPNLNEDLTCGNLLMWEAVTVKTEVIGITSMLNLHAGSQK.V

7

>100

4.1×103

Ib-2

60%

40–64

K.TGLDAITEVECFLNPEMGDPDENLR.G

Ib-1

51%

171–181

R.TKYPDGTITPK.N

8

>10

2.0×104

IV

55%

40–64

K.TGVDAITEVECFLNPEMGDPDNDLR.G

Ic

37%

334–349

R.VFDGTEKLPGDPDMIR.Y

9

>100

1.4×103

Ib-2

22%

40–69

K.TGLDAITEVECFLNPEMGDPDENLRGFSLK.L

    

10

<5–10

not done

Ib-2,Ic

20%

70–84

K.LSAENDFSSDSPERK.M

    

11

>10

negative

Ia,Ib-1

46%

40–64

K.TGVDAITEVECFLNPEMGDPDENLR.G

IV

29%

94–135

R.IPLPNLNEDLTCGNLLMWEAVTVKTEVIGITSMLNLHAGSQK.V

     

221–256

R.YFGTFTGGENVPPVLHVTNTATTVLLDEQGVGPLCK.A

    

13

>100

2.2×104

Ib-2

72%

40–64

K.TGLDAITEVECFLNPEMGDPDENLR.G

IV

53%

350–360

R.YIDRQGQLQTK.M

14

negative

negative

Ib-2

35%

40–64

K.TGLDAITEVECFLNPEMGDPDENLR.G

    

15

>10

2.4×104

IV

64%

40–64

K.TGVDAITEVECFLNPEMGDPDNDLR.G

Ic

42%

334–349

R.VFDGTEKLPGDPDMIR.Y

16

>10

not done

Ia, Ib-1

56%

201–215

K.NNAYPVECWVPDPSR.N

IV

23%

94–135

R.IPLPNLNEDLTCGNLLMWEAVTVKTEVIGITSMLNLHAGSQK.V

17

<5

5×101

 

not detected

 

not detected

    

18

>10

1.9×104

Ia, Ib-1,Ic

19%

40–69

K.TGVDAITEVECFLNPEMGDPDENLRGFSLK.L

    

19

>10

negative

Ia, Ib-1

64%

40–64

K.TGVDAITEVECFLNPEMGDPDENLR.G

IV

44%

40–64

K.TGVDAITEVECFLNPEMGDPDNDLR.G

     

221–256

R.YFGTFTGGENVPPVLHVTNTATTVLLDEQGVGPLCK.A

    
  1. For those subjects in whom peptides from VP1 were detected the number of decoy cells, the viral load in serum samples, the dominant viral subtype identified, and percent sequence coverage of VP1 protein are listed. Serum samples were collected within 2 weeks of the urine sample (except for patient 9 where the interval was 4 months). The peptides identified that defined the dominant viral subtype (based on greater BKV VP1 protein sequence coverage) are shown. In some cases the presence of two peptides gave evidence for a precise subtype specification. Further, peptides demonstrating the presence of co-infection with a different viral subtype are also shown where co-infection was observed. Residues highlighted in bold differ between the subtype groups Ia,Ib-1, Ic or Ib-2 or IV.